Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials
- PMID: 12069980
- PMCID: PMC127288
- DOI: 10.1128/AAC.46.7.2238-2243.2002
Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials
Abstract
Acyclovir cream has been available for the treatment of herpes labialis in numerous countries outside the United States for over a decade. Evidence for its efficacy comes from a few small clinical trials conducted in the 1980s. To examine more comprehensively the efficacy and safety of this formulation, we conducted two independent, identical, parallel, randomized, double-blind, vehicle-controlled, large-scale multicenter clinical trials. Healthy adults with a history of frequent herpes labialis were recruited from the general population, screened for eligibility, randomized equally to 5% acyclovir cream or vehicle control, given study medication, and told to self-initiate treatment five times daily for 4 days beginning within 1 h of the onset of a recurrent episode. The number of patients who treated a lesion was 686 in study 1 and 699 in study 2. In study 1, the mean duration of episodes was 4.3 days for patients treated with acyclovir cream and 4.8 days for those treated with the vehicle control (hazards ratio [HR] = 1.23; 95% confidence interval [CI], 1.06 to 1.44; P = 0.007). In study 2, the mean duration of episodes was 4.6 days for patients treated with acyclovir cream and 5.2 days for those treated with the vehicle control (HR = 1.24; 95% CI, 1.06 to 1.44; P = 0.006). Efficacy was apparent whether therapy was initiated "early" (prodrome or erythema lesion stage) or "late" (papule or vesicle stage). There was a statistically significant reduction in the duration of lesion pain in both studies. Acyclovir cream did not prevent the development of classical lesions (progression to vesicles, ulcers, and/or crusts). Adverse events were mild and infrequent.
Figures




Similar articles
-
Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group.JAMA. 1997 May 7;277(17):1374-9. JAMA. 1997. PMID: 9134943 Clinical Trial.
-
Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: a randomized, double-blind, placebo-controlled trial. Penciclovir Cream Herpes Labialis Study Group.Clin Ther. 2000 Jan;22(1):76-90. doi: 10.1016/s0149-2918(00)87979-5. Clin Ther. 2000. PMID: 10688392 Clinical Trial.
-
Effective treatment of herpes simplex labialis with penciclovir cream: combined results of two trials.J Am Dent Assoc. 2002 Mar;133(3):303-9. doi: 10.14219/jada.archive.2002.0169. J Am Dent Assoc. 2002. PMID: 11934185 Clinical Trial.
-
Acyclovir in the management of herpes labialis.J Antimicrob Chemother. 1983 Sep;12 Suppl B:95-103. doi: 10.1093/jac/12.suppl_b.95. J Antimicrob Chemother. 1983. PMID: 6355056 Review.
-
The role of topical 5% acyclovir and 1% hydrocortisone cream (Xerese™) in the treatment of recurrent herpes simplex labialis.Postgrad Med. 2010 Sep;122(5):1-6. doi: 10.3810/pgm.2010.09.2216. Postgrad Med. 2010. PMID: 20873400 Review.
Cited by
-
Stratum Corneum Sampling to Assess Bioequivalence between Topical Acyclovir Products.Pharm Res. 2019 Nov 14;36(12):180. doi: 10.1007/s11095-019-2707-3. Pharm Res. 2019. PMID: 31728737 Free PMC article.
-
Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy.Clin Microbiol Rev. 2003 Jan;16(1):114-28. doi: 10.1128/CMR.16.1.114-128.2003. Clin Microbiol Rev. 2003. PMID: 12525428 Free PMC article. Review.
-
Antiviral effects of blackberry extract against herpes simplex virus type 1.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Sep;112(3):e31-5. doi: 10.1016/j.tripleo.2011.04.007. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011. PMID: 21827957 Free PMC article.
-
A novel drug delivery system using acyclovir nanofiber patch for topical treatment of recurrent herpes labialis: A randomized clinical trial.Clin Exp Dent Res. 2022 Feb;8(1):184-190. doi: 10.1002/cre2.512. Epub 2021 Dec 5. Clin Exp Dent Res. 2022. PMID: 34865318 Free PMC article. Clinical Trial.
-
Treatment and prevention of herpes labialis.Can Fam Physician. 2008 Dec;54(12):1683-7. Can Fam Physician. 2008. PMID: 19074705 Free PMC article. Review.
References
-
- Fiddian, A. P., and L. Ivanyi. 1983. Topical acyclovir in the management of recurrent herpes labialis. Br. J. Dermatol. 109:321-326. - PubMed
-
- Green, J. A., S. L. Spruance, G. Wenerstrom, and M. W. Piepkorn. 1985. Post-herpetic erythema multiforme prevented with prophylactic oral acyclovir. Ann. Intern. Med. 102:632-633. - PubMed
-
- Harris, E. K., and A. Albert. 1991. Survivorship analysis for clinical studies. Marcel Dekker, New York, N.Y.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical